tirzepatide surmount-1 trial weight loss non-diabetic Lilly Shows Superiority in SURMOUNT-3 and 4 Clinical trials of subcutaneous tirzepatide

Any dose reduction strategy represents off-label clinical judgment and should be discussed with your prescribing physician, who may suggest gradually reducing the dose by one step every 46 weeks based on individual circumstances

This delay can lead to increased gas production and retention, primarily contributing to bloating

Gowani evaluates your health history, weight-loss challenges, and goals before determining whether Wegovy is an appropriate option, ensuring treatment is tailored to your individual needs

If you have any questions or concerns about how your medications might affect your surgery, please contact our office

What sets Newport Beach UC apart is the emphasis on patient education